Evidence map›Paper›PMID 28123851›Full record

ArticleAmerican journal of cancer research2017

The fate of BRCA1-related germline mutations in triple-negative breast tumors.

Vassiliki Kotoula, Florentia Fostira, Kyriaki Papadopoulou, Paraskevi Apostolou, Eleftheria Tsolaki, Georgios Lazaridis, Kyriaki Manoussou, Flora Zagouri, Dimitrios Pectasides, Ioannis Vlachos and 13 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Vassiliki KotoulaDepartment of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of MedicineThessaloniki, Greece; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of ThessalonikiThessaloniki, Greece.
Florentia FostiraMolecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research NCSR Demokritos Athens, Greece.
Kyriaki PapadopoulouLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki Thessaloniki, Greece.
Paraskevi ApostolouMolecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research NCSR Demokritos Athens, Greece.
Eleftheria TsolakiLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki Thessaloniki, Greece.
Georgios LazaridisDepartment of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine Thessaloniki, Greece.
Kyriaki ManoussouSection of Biostatistics, Hellenic Cooperative Oncology Group, Data Office Athens, Greece.
Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine Athens, Greece.
Dimitrios PectasidesOncology Section, Second Department of Internal Medicine, Hippokration Hospital Athens, Greece.
Ioannis VlachosMolecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research NCSR DemokritosAthens, Greece; DIANA-Lab, Department of Computer and Communication Engineering, University of ThessalyVolos, Greece.
Ioannis TikasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki Thessaloniki, Greece.
Sotiris LakisLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki Thessaloniki, Greece.
Irene KonstantopoulouMolecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research NCSR Demokritos Athens, Greece.
George PentheroudakisDepartment of Medical Oncology, Ioannina University Hospital Ioannina, Greece.
Helen GogasFirst Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine Athens, Greece.
Pavlos PapakostasOncology Unit, Hippokration Hospital Athens, Greece.
Christos ChristodoulouSecond Department of Medical Oncology, Metropolitan Hospital Piraeus, Greece.
Dimitrios BafaloukosFirst Department of Medical Oncology, Metropolitan Hospital Piraeus, Greece.
Evangelia RazisThird Department of Medical Oncology, Hygeia Hospital Athens, Greece.
Vasilios KaravasilisDepartment of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine Thessaloniki, Greece.
Christina BamiasNational and Kapodistrian University of Athens, Medical School, Department of Hygiene, Epidemiology and Medical Statistics Athens, Greece.
Drakoulis YannoukakosMolecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research NCSR Demokritos Athens, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of ThessalonikiThessaloniki, Greece; Aristotle University of ThessalonikiThessaloniki, Greece.
Aristotle University of Thessaloniki · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The preservation of pathogenic

Indexed as

adjuvant chemotherapyBRCA1BRCA2germlinehaploinsufficiencymutant-LOHmutation reversionsomaticTNBCTP53

Identifiers

PMID28123851
PMCPMC5250684
OpenAlexW2584766998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.